Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Moderna mRNA-1273Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(50%)

Phase Distribution

Phase 2/3
1
50%
Phase 2
1
50%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 2/3Combined phases
1(50.0%)

Highest Phase Reached

Phase 2/3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 2/3

Trials by Phase

Phase 21 (50.0%)
Phase 2/31 (50.0%)

Trials by Status

completed150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_2

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
completedphase_2_3

Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

NCT05168813

Clinical Trials (2)

Showing 2 of 2 trials
NCT05000216Phase 2

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Terminated
NCT05168813Phase 2/3

Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

Completed

All 2 trials loaded

Drug Details

Intervention Type
Biological
Total Trials
2